Does the media prefer BMEA or SOPH?

In the previous week, SOPHiA GENETICS had 7 more articles in the media than Biomea Fusion. MarketBeat recorded 8 mentions for SOPHiA GENETICS and 1 mentions for Biomea Fusion. SOPHiA GENETICS's average media sentiment score of 0.09 beat Biomea Fusion's score of 0.00 indicating that SOPHiA GENETICS is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biomea Fusion 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SOPHiA GENETICS 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is BMEA or IRD more profitable?

Biomea Fusion has a net margin of 0.00% compared to Opus Genetics' net margin of -892.36%. Biomea Fusion's return on equity of -265.37% beat Opus Genetics' return on equity. Company Net Margins Return on Equity Return on Assets Biomea Fusion N/A -265.37% -103.96% Opus Genetics -892.36% -338.88% -191.21%

Does the media refer more to BMEA or IRD?

In the previous week, Opus Genetics had 5 more articles in the media than Biomea Fusion. MarketBeat recorded 6 mentions for Opus Genetics and 1 mentions for Biomea Fusion. Opus Genetics' average media sentiment score of 0.17 beat Biomea Fusion's score of 0.00 indicating that Opus Genetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biomea Fusion 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Opus Genetics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is BMEA or UPB more profitable?

Biomea Fusion has a net margin of 0.00% compared to Upstream Bio's net margin of -4,718.96%. Upstream Bio's return on equity of -43.82% beat Biomea Fusion's return on equity. Company Net Margins Return on Equity Return on Assets Biomea Fusion N/A -265.37% -103.96% Upstream Bio -4,718.96% -43.82% -42.27%

Does the media prefer BMEA or UPB?

In the previous week, Upstream Bio had 1 more articles in the media than Biomea Fusion. MarketBeat recorded 2 mentions for Upstream Bio and 1 mentions for Biomea Fusion. Biomea Fusion's average media sentiment score of 0.00 beat Upstream Bio's score of -0.76 indicating that Biomea Fusion is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biomea Fusion 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Upstream Bio 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative

Which has preferable earnings & valuation, BMEA or NMRA?

Biomea Fusion is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biomea Fusion N/A N/A -$61.80M -$0.68 N/A Neumora Therapeutics N/A N/A -$236.93M -$1.33 N/A

Is BMEA or NMRA more profitable?

Neumora Therapeutics' return on equity of -181.70% beat Biomea Fusion's return on equity. Company Net Margins Return on Equity Return on Assets Biomea Fusion N/A -265.37% -103.96% Neumora Therapeutics N/A -181.70% -119.15%

Does the media refer more to BMEA or NMRA?

In the previous week, Neumora Therapeutics had 1 more articles in the media than Biomea Fusion. MarketBeat recorded 2 mentions for Neumora Therapeutics and 1 mentions for Biomea Fusion. Biomea Fusion's average media sentiment score of 0.00 beat Neumora Therapeutics' score of -0.77 indicating that Biomea Fusion is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biomea Fusion 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Neumora Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative

Which has stronger valuation & earnings, AMRN or BMEA?

Amarin has higher revenue and earnings than Biomea Fusion. Amarin is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Amarin $216.76M 1.54 -$38.80M -$0.65 N/A Biomea Fusion N/A N/A -$61.80M -$0.68 N/A

Is AMRN or BMEA more profitable?

Biomea Fusion has a net margin of 0.00% compared to Amarin's net margin of -15.51%. Amarin's return on equity of -2.99% beat Biomea Fusion's return on equity. Company Net Margins Return on Equity Return on Assets Amarin -15.51% -2.99% -2.07% Biomea Fusion N/A -265.37% -103.96%

Biomea Fusion (BMEA) Competitors

$1.23 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$1.26 +0.03 (+2.36%)

As of 07:25 PM Eastern

Compare

BMEA vs. SOPH, IRD, UPB, NMRA, and AMRN

Should you buy Biomea Fusion stock or one of its competitors? MarketBeat compares Biomea Fusion with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Biomea Fusion include SOPHiA GENETICS (SOPH), Opus Genetics (IRD), Upstream Bio (UPB), Neumora Therapeutics (NMRA), and Amarin (AMRN). These companies are all part of the "pharmaceutical products" industry.

How does Biomea Fusion compare to SOPHiA GENETICS?

Biomea Fusion (NASDAQ:BMEA) and SOPHiA GENETICS (NASDAQ:SOPH) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, media sentiment, earnings, risk, analyst recommendations, dividends and valuation.

Biomea Fusion has a net margin of 0.00% compared to SOPHiA GENETICS's net margin of -44.48%. SOPHiA GENETICS's return on equity of -62.74% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biomea Fusion	N/A	-265.37%	-103.96%
SOPHiA GENETICS	-44.48%	-62.74%	-21.85%

Biomea Fusion has higher earnings, but lower revenue than SOPHiA GENETICS. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biomea Fusion	N/A	N/A	-$61.80M	-$0.68	N/A
SOPHiA GENETICS	$77.27M	5.68	-$79M	-$0.52	N/A

Biomea Fusion has a beta of -0.31, suggesting that its stock price is 131% less volatile than the broader market. Comparatively, SOPHiA GENETICS has a beta of 0.98, suggesting that its stock price is 2% less volatile than the broader market.

Biomea Fusion currently has a consensus target price of $8.50, indicating a potential upside of 591.06%. SOPHiA GENETICS has a consensus target price of $7.50, indicating a potential upside of 43.40%. Given Biomea Fusion's stronger consensus rating and higher possible upside, analysts plainly believe Biomea Fusion is more favorable than SOPHiA GENETICS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
SOPHiA GENETICS	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, SOPHiA GENETICS had 7 more articles in the media than Biomea Fusion. MarketBeat recorded 8 mentions for SOPHiA GENETICS and 1 mentions for Biomea Fusion. SOPHiA GENETICS's average media sentiment score of 0.09 beat Biomea Fusion's score of 0.00 indicating that SOPHiA GENETICS is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biomea Fusion	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
SOPHiA GENETICS	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

96.7% of Biomea Fusion shares are held by institutional investors. Comparatively, 31.6% of SOPHiA GENETICS shares are held by institutional investors. 10.6% of Biomea Fusion shares are held by company insiders. Comparatively, 4.9% of SOPHiA GENETICS shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Biomea Fusion beats SOPHiA GENETICS on 8 of the 15 factors compared between the two stocks.

How does Biomea Fusion compare to Opus Genetics?

Biomea Fusion (NASDAQ:BMEA) and Opus Genetics (NASDAQ:IRD) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

Biomea Fusion has a net margin of 0.00% compared to Opus Genetics' net margin of -892.36%. Biomea Fusion's return on equity of -265.37% beat Opus Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biomea Fusion	N/A	-265.37%	-103.96%
Opus Genetics	-892.36%	-338.88%	-191.21%

Biomea Fusion has a beta of -0.31, meaning that its share price is 131% less volatile than the broader market. Comparatively, Opus Genetics has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market.

Biomea Fusion presently has a consensus price target of $8.50, suggesting a potential upside of 591.06%. Opus Genetics has a consensus price target of $10.77, suggesting a potential upside of 163.95%. Given Biomea Fusion's higher probable upside, research analysts clearly believe Biomea Fusion is more favorable than Opus Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Opus Genetics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.94

Opus Genetics has higher revenue and earnings than Biomea Fusion. Opus Genetics is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biomea Fusion	N/A	N/A	-$61.80M	-$0.68	N/A
Opus Genetics	$14.20M	23.72	-$49.59M	-$1.33	N/A

In the previous week, Opus Genetics had 5 more articles in the media than Biomea Fusion. MarketBeat recorded 6 mentions for Opus Genetics and 1 mentions for Biomea Fusion. Opus Genetics' average media sentiment score of 0.17 beat Biomea Fusion's score of 0.00 indicating that Opus Genetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biomea Fusion	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Opus Genetics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

96.7% of Biomea Fusion shares are held by institutional investors. Comparatively, 15.0% of Opus Genetics shares are held by institutional investors. 10.6% of Biomea Fusion shares are held by company insiders. Comparatively, 11.7% of Opus Genetics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Opus Genetics beats Biomea Fusion on 9 of the 16 factors compared between the two stocks.

How does Biomea Fusion compare to Upstream Bio?

Biomea Fusion (NASDAQ:BMEA) and Upstream Bio (NASDAQ:UPB) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, media sentiment, valuation, dividends, profitability, analyst recommendations and institutional ownership.

Biomea Fusion currently has a consensus price target of $8.50, indicating a potential upside of 591.06%. Upstream Bio has a consensus price target of $33.17, indicating a potential upside of 424.79%. Given Biomea Fusion's stronger consensus rating and higher probable upside, analysts clearly believe Biomea Fusion is more favorable than Upstream Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Upstream Bio	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Biomea Fusion has higher earnings, but lower revenue than Upstream Bio. Upstream Bio is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biomea Fusion	N/A	N/A	-$61.80M	-$0.68	N/A
Upstream Bio	$2.85M	120.68	-$143.44M	-$2.91	N/A

Biomea Fusion has a net margin of 0.00% compared to Upstream Bio's net margin of -4,718.96%. Upstream Bio's return on equity of -43.82% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biomea Fusion	N/A	-265.37%	-103.96%
Upstream Bio	-4,718.96%	-43.82%	-42.27%

96.7% of Biomea Fusion shares are owned by institutional investors. 10.6% of Biomea Fusion shares are owned by company insiders. Comparatively, 16.5% of Upstream Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Upstream Bio had 1 more articles in the media than Biomea Fusion. MarketBeat recorded 2 mentions for Upstream Bio and 1 mentions for Biomea Fusion. Biomea Fusion's average media sentiment score of 0.00 beat Upstream Bio's score of -0.76 indicating that Biomea Fusion is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biomea Fusion	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Upstream Bio	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

Biomea Fusion has a beta of -0.31, meaning that its stock price is 131% less volatile than the broader market. Comparatively, Upstream Bio has a beta of 1.1, meaning that its stock price is 10% more volatile than the broader market.

Summary

Biomea Fusion beats Upstream Bio on 9 of the 15 factors compared between the two stocks.

How does Biomea Fusion compare to Neumora Therapeutics?

Biomea Fusion (NASDAQ:BMEA) and Neumora Therapeutics (NASDAQ:NMRA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, media sentiment, dividends, risk and analyst recommendations.

96.7% of Biomea Fusion shares are held by institutional investors. Comparatively, 47.7% of Neumora Therapeutics shares are held by institutional investors. 10.6% of Biomea Fusion shares are held by company insiders. Comparatively, 26.9% of Neumora Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Neumora Therapeutics had 1 more articles in the media than Biomea Fusion. MarketBeat recorded 2 mentions for Neumora Therapeutics and 1 mentions for Biomea Fusion. Biomea Fusion's average media sentiment score of 0.00 beat Neumora Therapeutics' score of -0.77 indicating that Biomea Fusion is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biomea Fusion	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Neumora Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

Biomea Fusion is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biomea Fusion	N/A	N/A	-$61.80M	-$0.68	N/A
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.33	N/A

Biomea Fusion presently has a consensus price target of $8.50, suggesting a potential upside of 591.06%. Neumora Therapeutics has a consensus price target of $6.86, suggesting a potential upside of 325.91%. Given Biomea Fusion's stronger consensus rating and higher possible upside, analysts plainly believe Biomea Fusion is more favorable than Neumora Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Neumora Therapeutics	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.60

Neumora Therapeutics' return on equity of -181.70% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biomea Fusion	N/A	-265.37%	-103.96%
Neumora Therapeutics	N/A	-181.70%	-119.15%

Biomea Fusion has a beta of -0.31, indicating that its share price is 131% less volatile than the broader market. Comparatively, Neumora Therapeutics has a beta of 2.73, indicating that its share price is 173% more volatile than the broader market.

Summary

Biomea Fusion beats Neumora Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Biomea Fusion compare to Amarin?

Amarin (NASDAQ:AMRN) and Biomea Fusion (NASDAQ:BMEA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends, profitability and media sentiment.

Amarin currently has a consensus target price of $12.00, indicating a potential downside of 24.86%. Biomea Fusion has a consensus target price of $8.50, indicating a potential upside of 591.06%. Given Biomea Fusion's stronger consensus rating and higher probable upside, analysts plainly believe Biomea Fusion is more favorable than Amarin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarin	2 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Biomea Fusion has a net margin of 0.00% compared to Amarin's net margin of -15.51%. Amarin's return on equity of -2.99% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amarin	-15.51%	-2.99%	-2.07%
Biomea Fusion	N/A	-265.37%	-103.96%

22.3% of Amarin shares are held by institutional investors. Comparatively, 96.7% of Biomea Fusion shares are held by institutional investors. 4.2% of Amarin shares are held by company insiders. Comparatively, 10.6% of Biomea Fusion shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Amarin has higher revenue and earnings than Biomea Fusion. Amarin is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amarin	$216.76M	1.54	-$38.80M	-$0.65	N/A
Biomea Fusion	N/A	N/A	-$61.80M	-$0.68	N/A

Amarin has a beta of 0.82, meaning that its share price is 18% less volatile than the broader market. Comparatively, Biomea Fusion has a beta of -0.31, meaning that its share price is 131% less volatile than the broader market.

In the previous week, Amarin had 15 more articles in the media than Biomea Fusion. MarketBeat recorded 16 mentions for Amarin and 1 mentions for Biomea Fusion. Amarin's average media sentiment score of 0.56 beat Biomea Fusion's score of 0.00 indicating that Amarin is being referred to more favorably in the media.

Company	Overall Sentiment
Amarin	Positive
Biomea Fusion	Neutral

Summary

Amarin beats Biomea Fusion on 9 of the 16 factors compared between the two stocks.

Get Biomea Fusion News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BMEA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BMEA vs. The Competition

Export

Metric	Biomea Fusion	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$88.93M	$3.45B	$6.45B	$12.39B
Dividend Yield	N/A	2.30%	2.69%	5.83%
P/E Ratio	-1.81	19.75	24.92	23.98
Price / Sales	N/A	330.11	529.01	109.54
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	2.93	8.29	10.79	6.50
Net Income	-$61.80M	$23.85M	$3.56B	$336.88M
7 Day Performance	6.03%	5.21%	1.67%	-0.22%
1 Month Performance	-13.38%	2.19%	0.43%	0.77%
1 Year Performance	-27.22%	60.99%	32.84%	31.57%

Biomea Fusion Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BMEA Biomea Fusion	1.6827 of 5 stars	$1.23 flat	$8.50 +591.1%	-32.0%	$88.93M	N/A	N/A	50
SOPH SOPHiA GENETICS	2.4812 of 5 stars	$5.01 +2.7%	$7.50 +49.7%	+75.7%	$334.21M	$77.27M	N/A	520
IRD Opus Genetics	3.042 of 5 stars	$3.91 -3.2%	$10.67 +172.8%	+329.4%	$333.57M	$14.20M	N/A	14	Analyst Forecast
UPB Upstream Bio	1.856 of 5 stars	$6.10 flat	$33.17 +443.7%	-42.1%	$331.96M	$2.85M	N/A	38
NMRA Neumora Therapeutics	2.996 of 5 stars	$0.91 -48.6%	$7.67 +738.3%	+94.7%	$329.81M	N/A	N/A	108	Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BMEA) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biomea Fusion (BMEA) Competitors

BMEA vs. SOPH, IRD, UPB, NMRA, and AMRN

How does Biomea Fusion compare to SOPHiA GENETICS?

Summary

How does Biomea Fusion compare to Opus Genetics?

Summary

How does Biomea Fusion compare to Upstream Bio?

Summary

How does Biomea Fusion compare to Neumora Therapeutics?

Summary

How does Biomea Fusion compare to Amarin?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMEA vs. The Competition

Biomea Fusion Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biomea Fusion (BMEA) Competitors

BMEA vs. SOPH, IRD, UPB, NMRA, and AMRN

How does Biomea Fusion compare to SOPHiA GENETICS?

Is BMEA or SOPH more profitable?

Which has higher earnings & valuation, BMEA or SOPH?

Which has more risk & volatility, BMEA or SOPH?

Do analysts rate BMEA or SOPH?

Does the media prefer BMEA or SOPH?

Do insiders & institutionals believe in BMEA or SOPH?

Summary

How does Biomea Fusion compare to Opus Genetics?

Is BMEA or IRD more profitable?

Which has more volatility and risk, BMEA or IRD?

Do analysts prefer BMEA or IRD?

Which has higher earnings & valuation, BMEA or IRD?

Does the media refer more to BMEA or IRD?

Do institutionals and insiders have more ownership in BMEA or IRD?

Summary

How does Biomea Fusion compare to Upstream Bio?

Do analysts prefer BMEA or UPB?

Which has stronger valuation and earnings, BMEA or UPB?

Is BMEA or UPB more profitable?

Do institutionals & insiders believe in BMEA or UPB?

Does the media prefer BMEA or UPB?

Which has more volatility & risk, BMEA or UPB?

Summary

How does Biomea Fusion compare to Neumora Therapeutics?

Do insiders & institutionals have more ownership in BMEA or NMRA?

Does the media refer more to BMEA or NMRA?

Which has preferable earnings & valuation, BMEA or NMRA?

Do analysts recommend BMEA or NMRA?

Is BMEA or NMRA more profitable?

Which has more volatility and risk, BMEA or NMRA?

Summary

How does Biomea Fusion compare to Amarin?

Do analysts recommend AMRN or BMEA?

Is AMRN or BMEA more profitable?

Do institutionals & insiders believe in AMRN or BMEA?

Which has stronger valuation & earnings, AMRN or BMEA?

Which has more volatility and risk, AMRN or BMEA?

Does the media favor AMRN or BMEA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMEA vs. The Competition

Biomea Fusion Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools